3 Stocks in Which Mukul Agrawal Exited His Majority Stake in Q4

Synopsis: Ace investor Mukul Mahavir Agrawal exited his majority stake in OneSource Specialty Pharma, Pearl Global Industries, and Jagsonpal Pharmaceuticals during Q4 FY26, signaling portfolio reshuffling and a change in investment strategy.

Ace investor Mukul Mahavir Agrawal made notable portfolio changes in Q4 FY26 by exiting his majority stake in a few stocks, attracting market attention. As per the latest corporate shareholdings filed, Mukul Agrawal publicly holds 74 stocks with a net worth of over Rs. 7,027.2 crore, reflecting his strong presence in the market. Such moves may indicate profit booking or a shift in investment strategy. Tracking these changes helps investors understand market sentiment and stock outlook.  Here are a few stocks in which Mukul Mahavir Agrawal exited his majority stake in Q4 FY26

OneSource Specialty Pharma Limited

With a market capitalization of Rs. 20,326.14 crore, the shares of OneSource Specialty Pharma Limited were currently trading at Rs. 1773.00 per equity share, rising nearly 0.26 percent from its previous day’s close price of Rs. 1768.40.

In the Shareholding Pattern of March 2026, OneSource Specialty Pharma Limited had a majority stake held by the promoters at 30.48 percent, foreign institutional investors at 17.50 percent, domestic institutional investors at 20.61 percent, and the public at 31.40 percent.

Ace investor Mukul Mahavir Agrawal exited his majority stake in OneSource Specialty Pharma Limited, reducing its holding from 1.05 percent (12 lakh shares) in December 2025 to below 1 percent by March 2026.

OneSource Specialty Pharma Limited is an Indian biopharmaceutical and contract development and manufacturing organization (CDMO) headquartered in Bengaluru, Karnataka. Formed in 2024 through the consolidation of three CDMO businesses under the Strides Group, it provides integrated development and manufacturing services across biologics, complex injectables, and drug-device combinations for global pharmaceutical clients.

Pearl Global Industries Limited

With a market capitalization of Rs. 7,130.48 crore, the shares of Pearl Global Industries Limited were currently trading at Rs. 1545.20 per equity share, down nearly 2.30 percent from its previous day’s close price of Rs. 1581.50.

In the Shareholding Pattern of March 2026, Pearl Global Industries Limited had a majority stake held by the promoters at 61.16 percent, foreign institutional investors at 6.48 percent, domestic institutional investors at 18.80 percent, and the public at 13.56 percent.

Ace investor Mukul Mahavir Agrawal exited his majority stake in Pearl Global Industries Limited, reducing its holding from 1.52 percent (7 lakh shares) in December 2025 to below 1 percent by March 2026.

Pearl Global Industries Limited is an Indian multinational apparel manufacturing company that provides end-to-end solutions for global fashion brands. Founded in 1987 and headquartered in Gurugram, it focuses on large-scale garment exports and increasingly on sustainable, traceable supply chains.

Jagsonpal Pharmaceuticals Limited

With a market capitalization of Rs. 1,332.55 crore, the shares of Jagsonpal Pharmaceuticals Limited were currently trading at Rs. 199 per equity share, down nearly 1.66 percent from its previous day’s close price of Rs. 202.35.

In the Shareholding Pattern of March 2026, Jagsonpal Pharmaceuticals Limited had a majority stake held by the promoters at 67.89 percent, foreign institutional investors at 2.44 percent, domestic institutional investors at 0.22 percent, and the public at 29.44 percent.

Ace investor Mukul Mahavir Agrawal exited his majority stake in Jagsonpal Pharmaceuticals Limited, reducing its holding from 1.73 percent (11.58 lakh shares) in December 2025 to below 1 percent by March 2026.

Jagsonpal Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Gurugram, Haryana, with its registered office in New Delhi. Founded in 1978, it develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs), primarily focusing on gynecology and orthopedics. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 3 Stocks in Which Mukul Agrawal Exited His Majority Stake in Q4 appeared first on Trade Brains.